CYDUCT Positioned to Help Define the Next Frontier in Precision Breast Health

CYduct’s intraductal platform targets the emerging convergence of precision risk assessment, biological insight, and early interception

CYduct Diagnostics, Inc. (OTCMKTS:CYDX)

WESTPORT, CT, UNITED STATES, August 12, 2026 /EINPresswire.com/ — CYduct Diagnostics, Inc. (OTCPK: CYDX) (“CYduct” or the “Company”), a women’s health company developing technologies to support earlier detection and more precise breast health management, believes breast cancer care is entering a new phase, one increasingly focused not only on detecting established disease, but on identifying risk earlier, understanding breast biology sooner, and creating opportunities for earlier, more personalized intervention.

Recent momentum in AI-enabled risk prediction, advanced imaging, molecular diagnostics, and precision therapeutics is accelerating this shift and moving the breast-health continuum upstream. For CYduct, this evolution strongly aligns with the company’s core strategy and long-standing focus on the breast intraductal environment.

Precision Risk Assessment → Earlier Identification → Intraductal Insight → Early Interception

CYduct is developing products designed to access and analyze information from the breast ductal environment, where most breast cancers originate. The company’s objective is to add a potentially valuable layer of breast-specific biological and visual insight alongside mammography, genetics, risk models, and established clinical assessment.

As the industry becomes increasingly capable of identifying women at elevated risk, a critical next question emerges: What is happening within the breast, and can that information help support earlier, more personalized action? CYduct is focused on helping address that question through its intraductal approach.
“We believe breast cancer care is moving toward a future where risk is identified earlier, breast biology is understood sooner, and intervention becomes increasingly personalized,” said Dom Gatto, CEO of CYduct Diagnostics. “CYduct is positioning its intraductal platform at the intersection of these trends, with the goal of helping move breast health beyond the detection of established disease toward precision assessment and early interception.”

CYduct believes this evolution has the potential to expand the opportunity beyond traditional breast cancer diagnostics into a broader precision breast-health and early-interception market, encompassing risk stratification, longitudinal surveillance, intraductal insight, and clinical decision support. The Company’s intraductal approach is designed to complement, not replace, mammography, genetics, and other established clinical tools, creating the potential for a differentiated position within an increasingly integrated breast-health ecosystem.

CYduct’s vision is to help establish the intraductal approach as a meaningful component of precision breast health, connecting advances in risk assessment with information from within the breast ducts that can help support increasingly individualized care.

• Precision Risk Assessment tells us who to watch.
• Intraductal Insight can help inform what comes next.

CYduct believes the convergence of these capabilities represents an important step in advancing breast health from image-based detection toward earlier molecular insight and ultimately, toward precision-driven early interception.

Additional information on its line of products will be available on the Company’s website at: www.CYductDX.com.

FORWARD-LOOKING STATEMENTS; ADDITIONAL INFORMATION
This press release contains forward-looking statements, including statements regarding CYduct’s plans, expectations, beliefs, objectives and future performance. Such statements may be identified by words such as “may,” “could,” “will,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “potential” and similar expressions. Forward-looking statements are based on management’s current assumptions, estimates and information and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied. Accordingly, such statements are not guarantees of future performance, and readers should not place undue reliance on them. Additional risks are described in the Company’s Annual Report and other filings with OTC Markets Group, available at www.otcmarkets.com. All forward-looking statements speak only as of the date of this release, and CYduct undertakes no obligation to update or revise them except as required by law.

CONTACT:
CYduct Diagnostics, Inc.
Investor Relations +1-888-545-9112
SOURCE: CYduct Diagnostics, Inc.

email us here
CYduct Diagnostics, Inc.
Elise Grubb

Media gallery